A Phase 1/2 Study of Vorinostat (Zolinza®) in Combination with Gemtuzumab Ozogamicin (Mylotarg®) and 5-Azacytidine (Vidaza®) in Patients ≥50 Years of Age with Relapsed/Refractory non-APL Acute Myeloid Leukemia (AML)